When First-Line Treatment for Mild Pemphigus Vulgaris Fails to Achieve Disease Control
Clinical Scenario
This protocol addresses patients with mild pemphigus vulgaris: involved body surface area (BSA) below 5%, with limited oral lesions not impairing food intake or requiring analgesics, and/or a PDAI score of 15 or less.
Previous Treatment — Disease Control Not Achieved
First-line therapy for mild pemphigus vulgaris — which may include rituximab (alone or in combination with corticosteroids), or systemic corticosteroids such as prednisone/prednisolone with or without adjuvant agents (azathioprine, mycophenolate mofetil, or mycophenolate sodium) — did not achieve disease control. This protocol defines the second-line step taken after that failure.
Second-Line Approach (Partial Overview)
At this stage, management involves modifying the corticosteroid or biologic component of the regimen based on which first-line therapy the patient received. The specific adjustment and the goal of achieving disease control are detailed in the full structured protocol below.
References
DOI: 10.1111/jdv.16752
- PV with involved body surface area (BSA) < 5 % and limited oral lesions not impairing food intake or requiring analgesics.
- PDAI score ≤ 15.
- Patients initially treated with prednisone/prednisolone 0.5-1.0 mg/kg/day alone: Add rituximab (two infusions of 1g two weeks apart) with a rapid decrease of oral prednisolone in order to stop corticosteroids after 3 or 4 months.
- Patients initially treated with prednisone/prednisolone 0.5-1.0 mg/kg/day plus rituximab: increase the dose of prednisolone up to 1 mg/kg/day.
- Disease control achieved.
View source ↗